

May 16, 2025

To

Listing Department,

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza,

Bandra Kurla Complex, Bandra (E),

MUMBAI -400 051

**Company Code No. AUROPHARMA** 

To

The Corporate Relations Department

**BSE LIMITED** 

Phiroz Jeejeebhoy Towers, 25<sup>th</sup> floor, Dalal Street,

MUMBAI -400 001

Company Code No. 524804

Dear Sir/Madam,

## Sub: Intimation of Board Meeting.

We hereby inform pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that a Meeting of the Board of Directors of the Company will be held on **Monday, May 26, 2025,** to consider and approve inter alia, the Standalone & Consolidated Audited Financial Results of the Company for the fourth quarter and financial year ended March 31, 2025.

Further to our letter dated March 25, 2025 whereby we informed the closure of Trading Window of the Company from April 1, 2025 until 48 hours from the date of declaration of the Audited Financial Results of the Company for the fourth quarter and financial year ended March 31, 2025, we inform you that the Trading Window will remain closed up to May 28, 2025 and shall be re-opened on May 29, 2025.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy Company Secretary

## AUROBINDO PHARMA LIMITED

(CIN: L24239TG1986PLC015190)

www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.